DHR

Danaher Corporation 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended October 1, 2004, and the nine-month period ended on the same date. Danaher Corporation operates in two primary segments: Process/Environmental Controls and Tools and Components. During this period, the company significantly expanded its Medical Technology platform within the Process/Environmental Controls segment through major acquisitions, including Radiometer A/S and Kaltenbach & Voigt GmbH (KaVo). All share and per-share data have been retroactively restated to reflect a two-for-one stock split completed in May 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated sales increased 33% in the quarter and 29% for the nine months compared to the prior year. Growth was driven by acquisitions (approx. 22% in Q3, 15.5% YTD), organic growth from existing businesses (9% in Q3, 10.5% YTD), and favorable currency translation (approx. 2-3%).
• Profitability: Net earnings rose 45% in the quarter and 44% YTD. Operating margins improved due to sales leverage, cost reduction initiatives (Danaher Business System), and higher margins in acquired businesses, partially offset by lower margins in newly acquired entities like KaVo.
• Acquisitions: The company spent approximately $1.37 billion on acquisitions in the first nine months of 2004, primarily for Radiometer ($684M) and KaVo ($412M). This resulted in a significant increase in goodwill (from $3.06B to $3.79B) and intangible assets.
• Liquidity: Cash and equivalents decreased from $1.23 billion (Dec 31, 2003) to $532 million (Oct 1, 2004) due to heavy acquisition spending. Total debt increased slightly to $1.31 billion, driven by accretion of LYONs notes and temporary borrowings for acquisitions.

Outlook, Risks, and Contingencies

• Guidance: Management expects year-over-year existing business growth rates to moderate in the fourth quarter as comparisons shift to stronger periods from late 2003. Capital spending for the full year is expected to be between $100 million and $120 million.
• Pending Acquisitions: The company has made offers to acquire a Canadian water quality company (approx. $185M) and a UK product identification company (approx. $158M). Both are subject to regulatory approval and expected to close in Q4 2004.
• Legal Contingency: A federal jury awarded a plaintiff approximately $8 million in damages for patent infringement regarding infrared thermometer technology. The company intends to appeal and believes the purchase agreement indemnifies them; management does not expect a material adverse effect.
• Risks: Key risks include currency exchange rate fluctuations (particularly the Euro), raw material cost increases (steel), integration challenges of new acquisitions, and potential softness in the semiconductor and retail markets.
• Accounting Changes: The company is evaluating the impact of new FASB standards regarding share-based payments, which may require expensing stock options starting in 2005.

Investor Verification Checklist

• Acquisition Integration: Verify the progress of integrating Radiometer and KaVo into the Medical Technology platform and the realization of projected synergies.
• Working Capital Trends: Monitor the increase in trade receivables and inventories to ensure they align with sales growth and do not signal collection or obsolescence issues.
• Debt Structure: Review the maturity profile of the $1.3 billion debt, specifically the $372 million Eurobond due in 2005 and the $563 million LYONs notes.
• Legal Exposure: Track the status of the patent infringement appeal and the potential for trebled damages or legal fees.
• Stock-Based Compensation: Assess the potential impact of the upcoming mandatory adoption of fair-value accounting for stock options on future earnings.